StockData
Mesoblast Ltd logo

Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.64−0.27 (-2.27%)

Close on Nov 18, 2026Market cap $1.51BP/E –Yield –

Mesoblast net income

Net income is the profit left for shareholders after every expense, interest and tax.

Mesoblast's net income for the twelve months ending Jun 30, 2023 was -$81.89M. For fiscal 2026 it was -$57.50M. The highest annual figure on record is -$4.13M in fiscal 2016.

Annual net income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$57.50M–
FY2025Jun 30, 2025-$102.14M–
FY2024Jun 30, 2024-$87.96M–
FY2023Jun 30, 2023-$81.89M–
FY2022Jun 30, 2022-$91.35M–
FY2021Jun 30, 2021-$98.81M–
FY2020Jun 30, 2020-$77.94M–
FY2019Jun 30, 2019-$89.80M–
FY2018Jun 30, 2018-$35.29M–
FY2017Jun 30, 2017-$76.82M–
FY2016Jun 30, 2016-$4.13M–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2023CQ2 2023Jun 30, 2023-$21.92M–
Q3 FY2023CQ1 2023Mar 31, 2023-$18.60M–
Q2 FY2023CQ4 2022Dec 31, 2022-$24.49M–
Q1 FY2023CQ3 2022Sep 30, 2022-$16.88M–
Q4 FY2022CQ2 2022Jun 30, 2022-$21.46M–
Q3 FY2022CQ1 2022Mar 31, 2022-$21.30M–
Q2 FY2022CQ4 2021Dec 31, 2021-$25.95M–
Q1 FY2022CQ3 2021Sep 30, 2021-$22.65M–
Q4 FY2021CQ2 2021Jun 30, 2021-$22.06M–
Q3 FY2021CQ1 2021Mar 31, 2021-$26.52M–
Q2 FY2021CQ4 2020Dec 31, 2020-$25.69M–
Q1 FY2021CQ3 2020Sep 30, 2020-$24.54M–
Q4 FY2020CQ2 2020Jun 30, 2020-$32.61M–
Q3 FY2020CQ1 2020Mar 31, 2020-$15.26M–
Q2 FY2020CQ4 2019Dec 31, 2019-$24.58M–
Q1 FY2020CQ3 2019Sep 30, 2019-$5.48M–
Q4 FY2019CQ2 2019Jun 30, 2019-$20.73M–
Q3 FY2019CQ1 2019Mar 31, 2019-$24.97M–
Q2 FY2019CQ4 2018Dec 31, 2018-$24.60M-279.6%
Q1 FY2019CQ3 2018Sep 30, 2018-$19.50M–
Q4 FY2018CQ2 2018Jun 30, 2018-$20.83M–
Q3 FY2018CQ1 2018Mar 31, 2018-$21.14M–
Q2 FY2018CQ4 2017Dec 31, 2017$13.70M–

More Mesoblast figures

See a number that looks wrong?